Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study
暂无分享,去创建一个
Graham M Lord | J. Sterne | K. Channon | W. Koenig | J. Mayet | D. Francis | D. Perera | A. Trickey | M. Thursz | F. Asselbergs | Anoop S. V. Shah | R. Kharbanda | V. Panoulas | D. Haskard | N. Melikian | J. Davies | M. O’Sullivan | B. Williams | A. Hartley | A. Kaura | P. Elliott | B. Glampson | K. Woods | R. Khamis | R. Patel | A. Mulla | J. Omigie | A. Shah | A. Shah | A. Shah | H. Hemmingway | A. D. Shah
[1] P. Libby,et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial , 2021, The Lancet.
[2] P. Nordbeck,et al. C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study , 2021, Frontiers in Cardiovascular Medicine.
[3] G. Hankey,et al. Colchicine in Patients with Chronic Coronary Disease. , 2020, The New England journal of medicine.
[4] Graham M Lord,et al. Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data , 2020, The Lancet.
[5] Graham M Lord,et al. Prognostic significance of troponin level in 3121 patients presenting with atrial fibrillation (The NIHR Health Informatics Collaborative TROP‐AF study) , 2020, Journal of the American Heart Association.
[6] Graham M Lord,et al. Association of troponin level and age with mortality in 250 000 patients: cohort study across five UK acute care centres , 2019, BMJ.
[7] G. Niccoli,et al. Optical coherence tomography and C-reactive protein in risk stratification of acute coronary syndromes. , 2019, International journal of cardiology.
[8] M. Shao,et al. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial , 2019, JAMA cardiology.
[9] P. Libby,et al. Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events , 2019, The New England journal of medicine.
[10] Katherine E Henson,et al. Risk of Suicide After Cancer Diagnosis in England , 2018, JAMA psychiatry.
[11] P. Ridker,et al. Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention? , 2018, European heart journal.
[12] Samin K. Sharma,et al. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions , 2018, European heart journal.
[13] P. Libby,et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial , 2017, The Lancet.
[14] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[15] C. Granger,et al. Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. , 2016, Journal of the American College of Cardiology.
[16] K. Rentsch,et al. Misdiagnosis of Myocardial Infarction Related to Limitations of the Current Regulatory Approach to Define Clinical Decision Values for Cardiac Troponin , 2015, Circulation.
[17] W. Koenig,et al. Correlation of concentrations of high-sensitivity troponin T and high-sensitivity C-reactive protein with plaque progression as measured by CT coronary angiography. , 2014, Journal of cardiovascular computed tomography.
[18] Y. Momiyama,et al. Inflammation, Atherosclerosis and Coronary Artery Disease , 2014, Clinical Medicine Insights. Cardiology.
[19] J. Gallacher,et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. , 2012, The New England journal of medicine.
[20] Jennifer G. Robinson,et al. Comparison of the Framingham and Reynolds Risk Scores for Global Cardiovascular Risk Prediction in the Multiethnic Women's Health Initiative , 2012, Circulation.
[21] Jennifer G. Robinson,et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis , 2012, The Lancet.
[22] J. Danesh,et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data , 2011, BMJ : British Medical Journal.
[23] Akiko Maehara,et al. A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.
[24] C. Meisinger,et al. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. , 2008, Clinical chemistry.
[25] N. Brunetti,et al. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. , 2006, International journal of cardiology.
[26] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[27] A. Döring,et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.
[28] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[29] A. Rebuzzi,et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.
[30] W. Weintraub,et al. Elevation of C-reactive protein in "active" coronary artery disease. , 1990, The American journal of cardiology.
[31] Fred S Apple,et al. Analytical characteristics of high-sensitivity cardiac troponin assays. , 2012, Clinical chemistry.
[32] E. Antman,et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. , 1998, Journal of the American College of Cardiology.